Anti-CXCR4 monoclonal antibody - Eli LillyAlternative Names: CXCR4 Mab - Eli Lilly
Latest Information Update: 08 Feb 2012
At a glance
- Originator Eli Lilly
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action CXCR4 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Jan 2012 Discontinued - Phase-I for Cancer in USA (Parenteral)
- 16 Jun 2011 Phase-I clinical trials in Cancer in USA (Parenteral)